EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of Meropenem and Meropenem-Amikacin Combination against Carbapenem-resistant and Multidrug-resistant Pseudomonas aeruginosa Isolates In vitro

Faranita Nurfadlilah, Agung Dwi Wahyu Widodo, Pepy Dwi Endraswari, Siti Rochmanah Oktaviani Sulikah

Journal of Pure and Applied Microbiology · 01.06.2026 · 20 (2) · 1214

DOI: 10.22207/jpam.20.2.07 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pure and Applied Microbiology, online erschienen am 18.04.2026. Verfasst von Faranita Nurfadlilah und 3 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) and multidrug-resistant P. aeruginosa (MDR-PA) pose major therapeutic challenges. The limited availability of new antibiotics necessitates evaluating rational combination therapies. This study aimed to compare the in vitro efficacy of meropenem versus meropenem-amikacin combination against carbapenem-resistant P. aeruginosa isolates (including CRPA and MDR-PA). An in vitro experimental study using the checkerboard method was performed on 10 clinical isolates (3 CRPA and 7 MDR-PA) obtained from Dr. Soetomo General Hospital, Surabaya (June-October 2025). Three isolates that showed a decrease in meropenem Minimum Inhibitory Concentration (MIC) to the susceptible range upon confirmatory testing were excluded from the combination synergy analysis. The effectiveness of the combination was evaluated by comparing the MIC of meropenem with that of the combination. Antibiotic interactions were analyzed using the Fractional Inhibitory Concentration Index. Data were analyzed using the Mann-Whitney U test, with the primary analysis focusing on the combined group of resistant isolates. The median MIC of meropenem for the combined CRPA and MDR-PA isolates was 32 µg/mL. The checkerboard test revealed an additive interaction as the dominant effect (71.4%), followed by synergistic (14.3%) and indifferent (14.3%) effects. No antagonistic effects were observed. Statistical analysis of the combined group showed that the meropenem-amikacin combination was significantly more effective in reducing the MIC compared to monodrug (median MIC combination: 4 µg/mL vs. monodrug: 32 µg/mL; P = 0.009). These findings support the consideration of this combination as a therapeutic option for such infections.

Zitieren

APA

Nurfadlilah, F., Widodo, A. D. W., Endraswari, P. D., & Sulikah, S. R. O. (2026). Comparison of Meropenem and Meropenem-Amikacin Combination against Carbapenem-resistant and Multidrug-resistant Pseudomonas aeruginosa Isolates In vitro. Journal of Pure and Applied Microbiology, 20(2), 1214. https://doi.org/10.22207/jpam.20.2.07

Vancouver

Nurfadlilah F, Widodo ADW, Endraswari PD, Sulikah SRO. Comparison of Meropenem and Meropenem-Amikacin Combination against Carbapenem-resistant and Multidrug-resistant Pseudomonas aeruginosa Isolates In vitro. Journal of Pure and Applied Microbiology. 2026;20(2):1214. doi:10.22207/jpam.20.2.07

BibTeX
@article{Nurfadlilah2026,
  author = {Nurfadlilah, Faranita and Widodo, Agung Dwi Wahyu and Endraswari, Pepy Dwi and Sulikah, Siti Rochmanah Oktaviani},
  title = {Comparison of Meropenem and Meropenem-Amikacin Combination against Carbapenem-resistant and Multidrug-resistant Pseudomonas aeruginosa Isolates In vitro},
  journal = {Journal of Pure and Applied Microbiology},
  year = {2026},
  volume = {20},
  number = {2},
  pages = {1214},
  doi = {10.22207/jpam.20.2.07}
}
Kostenlos starten →